Quest Diagnostics (DGX) EBIT (2009 - 2026)

Quest Diagnostics has disclosed EBIT across 18 years of filings, most recently posting $399.0 million for Q1 2026.

• EBIT for Q1 2026 came in at $399.0 million, up 15.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 15.59% YoY), and the FY2025 annual result was $1.6 billion, up 15.6% from the prior year.
• EBIT came in at $399.0 million for Q1 2026 at Quest Diagnostics, up from $386.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $513.0 million in Q1 2022 to a low of $135.0 million in Q4 2022.
• The 5-year median for EBIT is $355.0 million (2024), against an average of $352.4 million.
• Across the five-year window, EBIT plunged 74.81% in 2022 and jumped 97.78% in 2023, its largest moves.
• Quest Diagnostics' EBIT stood at $135.0 million in 2022, then jumped by 97.78% to $267.0 million in 2023, then soared by 35.21% to $361.0 million in 2024, then increased by 6.93% to $386.0 million in 2025, then climbed by 3.37% to $399.0 million in 2026.
• The last three EBIT figures came in at $399.0 million (Q1 2026), $386.0 million (Q4 2025), and $386.0 million (Q3 2025), per Business Quant data.